1,109 results on '"Siegmund, B."'
Search Results
2. OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study
3. OP35 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn’s disease: Results from the phase 3 VIVID 1 study
4. P144 Modulation of Immunometabolism via NLRX1 or PLXDC2: Novel Bimodal Mechanisms for the Treatment of Inflammatory Bowel Diseases
5. P739 Translating Pharmacokinetic and Efficacy Outcomes of NLRX1 Agonist NX-13: Contrasting a Pig Model and a Human Phase 1b Clinical Trial in Ulcerative Colitis
6. DOP71 Efficacy of once-daily, orally administered obefazimod in patients with moderately to severely active UC at weeks 8, 48, and 96 broken down by induction treatment dose
7. P567 Impact of recent thiopurine use on ozanimod safety in patients with ulcerative colitis: a post hoc analysis of the phase 3 True North study
8. OP06 Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study
9. P029 Loss of adipose tissue protects mice from intestinal inflammation
10. P789 Impact of risk factors for Janus kinase inhibitor use identified by the Pharmacovigilance Risk Assessment Committee on the safety and efficacy of ozanimod in patients with moderately to severely active ulcerative colitis
11. OP12 Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn’s Disease: Results from a phase 3 clinical trial
12. P738 Response to etrasimod treatment in ulcerative colitis is associated with a reduction of circulating B and pro-inflammatory T cells: a single-cell-based post-hoc sub-analysis of the ELEVATE UC 52 trial
13. DOP12 Efficacy and safety of obefazimod in UC patients at weeks 48 and 96 of an open-label maintenance study among clinical responders at week 8 of the Phase 2b induction trial
14. OP24 SPP1 in colitis-associated colon cancer
15. P178 Changes in composition and structure of ileal mucus in Crohn’s disease patients compared to healthy controls
16. P985 Efficacy and safety of de-escalation from 50 mg to 25 mg of oral, once-daily, obefazimod for the third and fifth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): An interim analysis
17. P862 Effects of induction and maintenance therapy with risankizumab on health-related quality of life outcomes in patients with moderately to severely active ulcerative colitis: A post-hoc analysis of Phase 2b/3 trials
18. P788 The effect of etrasimod on faecal calprotectin and high-sensitivity C-reactive protein: Results from the ELEVATE UC clinical programme
19. Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2).
20. Malassimilationssyndrom
21. Glutensensitive Enteropathie, Zöliakie
22. Ein globaler Consensus zu Definitionen, Diagnostik und Behandlungsmanagement des fibrostenotischen Morbus Crohn des terminalen Ileums
23. Efficacy of etrasimod at Week 52 among patients with clinical response at Week 12 compared with the overall ulcerative colitis population: post hoc analysis of the phase 3 ELEVATE UC 52 trial
24. Benefits of diagnostic gastroscopy before endoscopy with side-viewing optic: A retrospective dual-center study
25. Geschlechtsspezifische Unterschiede bei chronisch-entzündlichen Darmerkrankungen
26. Transitionsmedizin – strukturelle Lösungsansätze
27. Molekulare Diagnostik der infektiösen Gastroenteritis
28. Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.1) – Februar 2023 – AWMF-Registriernummer: 021-009
29. Autoren
30. Transitionsmedizin
31. Aktuelle therapeutische Strategien beim Morbus Crohn
32. Campylobacter jejuni impairs sodium transport and epithelial barrier function via cytokine release in human colon
33. P631 Long-term safety of vedolizumab versus other biologic agents in ulcerative colitis (UC) and Crohn’s Disease (CD): Results from a large multinational prospective observational study
34. P714 Mucosal healing in CD with vedolizumab versus other biologics: endoscopic outcomes during long-term routine care in a multinational observational study
35. P770 Autologous regulatory T cell transfer in patients with refractory ulcerative colitis: Interim report of a phase 1, dose-escalation trial
36. P506 Endoscopic and clinical outcomes of upadacitinib in patients with moderate to severe Crohn’s disease by baseline disease severity
37. P047 Osteopontin in colitis-associated carcinoma (CAC)
38. P441 Long-term CD treatment failure and dose modification rates with vedolizumab and other biologics: Results from a large prospective observational study
39. P013 Role of IL-36RA mutations in Crohn’s disease
40. DOP90 The association of endoscopic and histologic endpoints with faecal calprotectin and C-reactive protein in patients with moderately to severely active ulcerative colitis treated with mirikizumab
41. P020 Characterisation of mucus in patients with Crohn’s disease
42. P270 A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease
43. P575 Effect of etrasimod on immune cell subsets in colonic tissue of patients with ulcerative colitis: immunophenotyping analysis of colon biopsy samples from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
44. P071 T-cell, B-cell and monocytic infiltrations of myenteric plexus in IBD
45. P558 Etrasimod for the treatment of ulcerative colitis: analysis of infection rates from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials
46. DOP84 IBD-related hospitalization and surgery rates in biologic-naïve patients with IBD treated with vedolizumab versus other biologics: Results from a long-term, prospective, observational study
47. P574 Characterization of plasma inflammatory protein abundance in patients with ulcerative colitis treated with etrasimod: an exploratory analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
48. P048 Deep phenotyping of the peripheral immune cell compartment in Crohn‘s Disease
49. P544 Low TNF production and low TREM1 expression as negative predictors for remission under adalimumab therapy in Crohn′s Disease patients
50. Faecal microbiota transplantation—A clinical view
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.